NO20021035D0 - Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon - Google Patents

Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon

Info

Publication number
NO20021035D0
NO20021035D0 NO20021035A NO20021035A NO20021035D0 NO 20021035 D0 NO20021035 D0 NO 20021035D0 NO 20021035 A NO20021035 A NO 20021035A NO 20021035 A NO20021035 A NO 20021035A NO 20021035 D0 NO20021035 D0 NO 20021035D0
Authority
NO
Norway
Prior art keywords
methods
serotonin reuptake
selective serotonin
sexual dysfunction
rapidly
Prior art date
Application number
NO20021035A
Other languages
English (en)
Other versions
NO20021035L (no
NO330562B1 (no
Inventor
Karl Bruce Thor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021035(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20021035D0 publication Critical patent/NO20021035D0/no
Publication of NO20021035L publication Critical patent/NO20021035L/no
Publication of NO330562B1 publication Critical patent/NO330562B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021035A 1999-09-03 2002-03-01 Anvendelse av dapoksetin for fremstilling av et medikament for behandling eller handtering av seksuell dysfunksjon NO330562B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15243599P 1999-09-03 1999-09-03
PCT/US2000/020788 WO2001017521A1 (en) 1999-09-03 2000-08-22 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Publications (3)

Publication Number Publication Date
NO20021035D0 true NO20021035D0 (no) 2002-03-01
NO20021035L NO20021035L (no) 2002-05-02
NO330562B1 NO330562B1 (no) 2011-05-16

Family

ID=22542905

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20021035A NO330562B1 (no) 1999-09-03 2002-03-01 Anvendelse av dapoksetin for fremstilling av et medikament for behandling eller handtering av seksuell dysfunksjon
NO2012015C NO2012015I2 (no) 1999-09-03 2012-09-11 Dapoxetine

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2012015C NO2012015I2 (no) 1999-09-03 2012-09-11 Dapoxetine

Country Status (34)

Country Link
US (4) US7718705B1 (no)
EP (3) EP1889614A3 (no)
JP (1) JP3194734B2 (no)
KR (1) KR100719977B1 (no)
CN (1) CN1222283C (no)
AT (1) ATE318135T1 (no)
AU (1) AU762934B2 (no)
BE (1) BE2012C040I2 (no)
BG (1) BG65677B1 (no)
BR (1) BR0014166A (no)
CA (1) CA2383785C (no)
CY (1) CY2012028I2 (no)
CZ (1) CZ299712B6 (no)
DE (2) DE60026146T2 (no)
DK (1) DK1225881T3 (no)
EA (1) EA004101B1 (no)
EE (1) EE05315B1 (no)
ES (2) ES2256032T3 (no)
FR (1) FR12C0052I2 (no)
HK (1) HK1047545B (no)
HR (1) HRP20020189A2 (no)
HU (1) HU229150B1 (no)
IL (2) IL148159A0 (no)
LU (1) LU92204I2 (no)
MX (1) MXPA02001811A (no)
MY (1) MY125490A (no)
NO (2) NO330562B1 (no)
NZ (1) NZ517038A (no)
PL (1) PL211402B1 (no)
SI (1) SI1225881T1 (no)
TW (3) TWI367751B (no)
UA (1) UA75580C2 (no)
WO (1) WO2001017521A1 (no)
ZA (1) ZA200201407B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
BR0014166A (pt) * 1999-09-03 2002-05-14 Lilly Co Eli Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
CA2758923A1 (en) 2001-03-16 2002-09-26 Dmi Biosciences, Inc. Use of tramadol to delay ejaculation
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
CA2410966C (en) * 2002-11-01 2005-11-22 Craig J. Hudson Sexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE102009058321A1 (de) * 2009-12-15 2011-06-16 Ratiopharm Gmbh Schmelztablette, enthaltend Dapoxetin
KR101465077B1 (ko) 2010-07-06 2014-11-26 주식회사 네비팜 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
RU2463033C2 (ru) * 2010-08-06 2012-10-10 Василий Федорович Пятин Способ лечения преждевременной эякуляции
CN103100085A (zh) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 一种药物组合物
CN103130660B (zh) * 2011-11-25 2014-09-17 厦门福满药业有限公司 一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2014042416A1 (ko) * 2012-09-13 2014-03-20 주식회사 씨티씨바이오 다폭세틴 유리염기를 함유하는 경구용 조성물
KR101432905B1 (ko) 2012-12-11 2014-08-21 가톨릭대학교 산학협력단 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CN103735525B (zh) * 2014-02-12 2015-05-06 江苏仁寿药业有限公司 一种达泊西汀片剂及制备方法
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2016025541A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113181127A (zh) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀微丸片的制备方法
CN113143879A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀缓释片的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en) 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5151488A (en) * 1991-11-12 1992-09-29 The Mead Corporation Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5292962A (en) 1992-12-11 1994-03-08 Eli Lilly And Company Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2143049T3 (es) 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
JP3462505B2 (ja) 1995-10-13 2003-11-05 ノイロサーチ アクティーゼルスカブ ８−アザビシクロ［３．２．１］オクト−２−エン誘導体、それらの製造及び使用
US5758911A (en) * 1996-02-07 1998-06-02 Northrop Grumman Corporation Linear motion wind driven power plant
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
BR9809895A (pt) 1997-07-01 2000-08-01 Pfizer Prod Inc Formas de dosagem da sertralina de liberação retardada
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
ID24673A (id) 1997-07-01 2000-07-27 Pfizer Prod Inc Bentuk-bentuk penakaran larutan sertralina dalam kapsul gelatin
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
AU4819099A (en) 1998-06-19 2000-01-05 Eli Lilly And Company Inhibition of serotonin reuptake
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6150376A (en) 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
OA11662A (en) 1998-10-13 2004-12-08 Pfizer Prod Inc Sertraline oral concentrate.
AU4982300A (en) * 1999-05-06 2000-11-21 Pentech Pharmaceuticals, Inc. Regimen and kit for amelioration of premature ejaculation
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
BR0014166A (pt) * 1999-09-03 2002-05-14 Lilly Co Eli Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual

Also Published As

Publication number Publication date
US20050261377A1 (en) 2005-11-24
CN1222283C (zh) 2005-10-12
HRP20020189A2 (en) 2004-02-29
ES2393582T3 (es) 2012-12-26
CA2383785C (en) 2009-02-17
EP1889614A3 (en) 2010-09-22
KR100719977B1 (ko) 2007-05-21
HUP0202687A2 (hu) 2002-12-28
DK1225881T3 (da) 2006-06-12
MY125490A (en) 2006-08-30
DE60026146T2 (de) 2006-08-17
NO20021035L (no) 2002-05-02
ATE318135T1 (de) 2006-03-15
CY2012028I1 (el) 2017-04-05
EP1225881A1 (en) 2002-07-31
BG65677B1 (bg) 2009-06-30
EA004101B1 (ru) 2003-12-25
HK1047545A1 (en) 2003-02-28
NO2012015I1 (no) 2012-09-11
LU92204I2 (fr) 2013-07-23
EP1225881B1 (en) 2006-02-22
EP1671628A1 (en) 2006-06-21
BR0014166A (pt) 2002-05-14
US20140221497A1 (en) 2014-08-07
ZA200201407B (en) 2003-07-30
CZ299712B6 (cs) 2008-10-29
HUP0202687A3 (en) 2006-03-28
EP1671628B1 (en) 2012-10-03
MXPA02001811A (es) 2002-08-06
US7718705B1 (en) 2010-05-18
IL148159A (en) 2009-11-18
PL211402B1 (pl) 2012-05-31
DE122009000036I2 (de) 2010-05-06
TW200524582A (en) 2005-08-01
PL364924A1 (en) 2004-12-27
HK1091418A1 (en) 2007-01-19
TWI367751B (en) 2012-07-11
BG106461A (en) 2002-12-29
CZ2002784A3 (cs) 2002-09-11
EA200200324A1 (ru) 2002-08-29
DE122009000036I1 (de) 2009-11-05
NZ517038A (en) 2003-04-29
EE05315B1 (et) 2010-08-16
CY2012028I2 (el) 2017-04-05
TW201018459A (en) 2010-05-16
HK1047545B (en) 2006-09-22
NO2012015I2 (no) 2013-08-26
CN1387432A (zh) 2002-12-25
CA2383785A1 (en) 2001-03-15
FR12C0052I1 (no) 2012-05-10
IL148159A0 (en) 2002-09-12
UA75580C2 (uk) 2006-05-15
BE2012C040I2 (no) 2019-10-16
NO330562B1 (no) 2011-05-16
WO2001017521A1 (en) 2001-03-15
US20050215617A1 (en) 2005-09-29
JP2001089394A (ja) 2001-04-03
EE200200107A (et) 2003-04-15
EP1889614A2 (en) 2008-02-20
FR12C0052I2 (fr) 2013-08-16
ES2256032T3 (es) 2006-07-16
TWI312678B (en) 2009-08-01
DE60026146D1 (de) 2006-04-27
KR20020025252A (ko) 2002-04-03
AU6891100A (en) 2001-04-10
AU762934B2 (en) 2003-07-10
SI1225881T1 (sl) 2006-06-30
HU229150B1 (hu) 2013-09-30
JP3194734B2 (ja) 2001-08-06

Similar Documents

Publication Publication Date Title
BE2012C040I2 (no)
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
MXPA03004288A (es) Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
EA200001058A1 (ru) Новые способы лечения нервных расстройств
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
CY1118068T1 (el) Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας
PA8505301A1 (es) Metodo para tratar el mal de parkinson a traves de la administracion de ( - ) - 5 ceto-2-n- propilamino - tetrahidrotetralina
CR6602A (es) Metodos de uso de inhbidores selectivos de reasorcion de serotonina de rapido inicio, para tratar la disfuncion sexual
ECSP993026A (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
ECSP003771A (es) Metodo para prevenir la diarrea
EA200000514A1 (ru) Способ лечения эректильной дисфункции
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PRILIGY; NAT. REG. NO/DATE: MTNR 10-7834/35 20120514; FIRST REG. NO/DATE: FI , 24353/4 20090205

Spc suppl protection certif: 2012015

Filing date: 20120911

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PRILIGY; NAT. REG. NO/DATE: MTNR 10-7834/35 20120514; FIRST REG. NO/DATE: FI , 24353/4 20090205

Spc suppl protection certif: 2012015

Filing date: 20120911

Extension date: 20240205

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ALLERGAN SALES, US

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: ALLERGAN SALES, US

Spc suppl protection certif: 2012015

MK1K Patent expired